JP2023544143A5 - - Google Patents

Info

Publication number
JP2023544143A5
JP2023544143A5 JP2023519492A JP2023519492A JP2023544143A5 JP 2023544143 A5 JP2023544143 A5 JP 2023544143A5 JP 2023519492 A JP2023519492 A JP 2023519492A JP 2023519492 A JP2023519492 A JP 2023519492A JP 2023544143 A5 JP2023544143 A5 JP 2023544143A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023519492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/121286 external-priority patent/WO2022068810A1/zh
Publication of JP2023544143A publication Critical patent/JP2023544143A/ja
Publication of JP2023544143A5 publication Critical patent/JP2023544143A5/ja
Ceased legal-status Critical Current

Links

JP2023519492A 2020-09-29 2021-09-28 抗クローディン18.2および抗cd3二重特異性抗体およびその使用 Ceased JP2023544143A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011054428 2020-09-29
CN202011054428.6 2020-09-29
PCT/CN2021/121286 WO2022068810A1 (zh) 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途

Publications (2)

Publication Number Publication Date
JP2023544143A JP2023544143A (ja) 2023-10-20
JP2023544143A5 true JP2023544143A5 (cg-RX-API-DMAC7.html) 2024-10-07

Family

ID=80949663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519492A Ceased JP2023544143A (ja) 2020-09-29 2021-09-28 抗クローディン18.2および抗cd3二重特異性抗体およびその使用

Country Status (9)

Country Link
US (1) US20230357389A1 (cg-RX-API-DMAC7.html)
EP (1) EP4223778A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023544143A (cg-RX-API-DMAC7.html)
KR (1) KR20230079165A (cg-RX-API-DMAC7.html)
CN (1) CN116323676A (cg-RX-API-DMAC7.html)
AU (1) AU2021352532B2 (cg-RX-API-DMAC7.html)
CA (1) CA3200865A1 (cg-RX-API-DMAC7.html)
TW (1) TWI837517B (cg-RX-API-DMAC7.html)
WO (1) WO2022068810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023245103A1 (en) * 2022-03-28 2024-10-24 Fortvita Biologics (Singapore) Pte. Ltd. Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof.
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
KR20240101987A (ko) * 2022-12-23 2024-07-03 주식회사 와이바이오로직스 클라우딘-18.2에 특이적으로 결합하는 단클론항체 및 이의 용도
CN116813782B (zh) * 2023-08-10 2024-01-23 北京百普赛斯生物科技股份有限公司 一种Claudin-18.2特异性抗体及其应用
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP2920209B1 (en) * 2012-11-13 2020-08-05 BioNTech SE Agents for treatment of claudin expressing cancer diseases
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
BR112015010817A8 (pt) * 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201905259SA (en) * 2017-02-02 2019-08-27 Merck Patent Gmbh Preferred pairing of antibody domains
CA3053379A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN111247171A (zh) * 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
CA3098910A1 (en) * 2018-05-01 2019-11-07 Ambrx, Inc. A method for optimizing antibody expression
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
BR112021002032A2 (pt) * 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3

Similar Documents

Publication Publication Date Title
US11987635B2 (en) Anti-4-1BB antibodies and methods of making and using thereof
AU2018214223B2 (en) Low pH pharmaceutical composition comprising T cell engaging antibody constructs
JP6326137B2 (ja) 抗her2抗体及びその結合体
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
RU2558301C2 (ru) Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
AU2018295119B2 (en) Multi-specific antibodies and methods of making and using thereof
JP2022533538A5 (cg-RX-API-DMAC7.html)
CN116396386A (zh) Cd3抗体及其药物用途
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2012518039A5 (cg-RX-API-DMAC7.html)
JP2022169504A5 (cg-RX-API-DMAC7.html)
JP6933724B2 (ja) Nk細胞活性化融合タンパク質、nk細胞およびそれらを含む医薬組成物
AU2026202717A1 (en) Anti c-met antibodies
JP2025508317A5 (cg-RX-API-DMAC7.html)
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
CA3159155A1 (en) Anti-clec-1a antibodies and antigen-binding fragment thereof
JP2022502079A5 (cg-RX-API-DMAC7.html)
JP2025516590A5 (cg-RX-API-DMAC7.html)
CN114616245A (zh) 一种抗cd38的抗体及其用途
US20250376531A9 (en) Anti-4-1bb antibodies and methods of making and using thereof
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CA3304076A1 (en) Bispecific antibodies that bind cd3 and the ganglioside ngcgm3
TW202612728A (zh) 使用靶向表現her2之腫瘤之三特異性結合蛋白治療癌症之方法
HK40111323A (en) Multi-specific antibodies and methods of making and using thereof